

CorMedix Inc.  
Form 8-K  
December 14, 2015

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): December 14, 2015

CORMEDIX INC.  
(Exact Name of Registrant as Specified in Charter)

|  |  |  |
|--|--|--|
| Delaware<br>(State or Other Jurisdiction<br>of Incorporation)                              | 001-34673<br>(Commission<br>File Number) | 20-5894890<br>(IRS Employer<br>Identification No.) |
| 1430 US Highway 206, Suite 200, Bedminster, NJ<br>(Address of Principal Executive Offices) |  | 07921<br>(Zip Code)                                |

Registrant's Telephone Number, Including Area Code: (908) 517-9500

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

Item 8.01. Other Events.

On December 14, 2015, CorMedix issued a press release announcing enrollment and dosing of the first patient in its Phase 3 Neutrolin® trial in hemodialysis.

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

| Exhibit<br>No. | Description |
|----------------|-------------|
|----------------|-------------|

|             |  |
|-------------|--|
| <u>99.1</u> | Press release dated December 14, 2015. |
|-------------|--|

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORMEDIX INC.

Date: December 14, 2015

By: /s/ Randy Milby  
Name: Randy Milby  
Title: Chief Executive Officer